Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zunyi Medical Univ. hMAO-B compound 1l
- Development stage
- Unknown
- Lead developer
- Zunyi Medical University
01
Overview
Zunyi Medical Univ. hMAO-B compound 1l: sourced facts only. name: "Kinetics and reversibility studies confirmed that compound 1l acted as a competitive and reversible inhibitor of hMAO-B." [PMID:38894921]; target: "Kinetics and reversibility studies confirmed that compound 1l acted as a competitive and reversible inhibitor of hMAO-B." [PMID:38894921]; developer: "School of Bioengineering, Zhuhai Campus, Zunyi Medical University, Zhuhai 519041, China." [PMID:38894921]; stage: "Additionally, compound 1l could effectively inhibit the release of NO, TNF-α, and IL-1β in both LPS- and Aβ1-42-stimulated BV2 cells and attenuate the cytotoxicity induced by Aβ1-42." [PMID:38894921]
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on Zunyi Medical Univ. hMAO-B compound 1l.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zunyi Medical Univ. hMAO-B compound 1l.